These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31260298)

  • 1. Computationally Driven Structure Optimization, Synthesis, and Biological Evaluation of Imidazole-Based Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors.
    Lammi C; Sgrignani J; Arnoldi A; Lesma G; Spatti C; Silvani A; Grazioso G
    J Med Chem; 2019 Jul; 62(13):6163-6174. PubMed ID: 31260298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disrupting the PCSK9/LDLR protein-protein interaction by an imidazole-based minimalist peptidomimetic.
    Stucchi M; Grazioso G; Lammi C; Manara S; Zanoni C; Arnoldi A; Lesma G; Silvani A
    Org Biomol Chem; 2016 Oct; 14(41):9736-9740. PubMed ID: 27722650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
    Ly K; Essalmani R; Desjardins R; Seidah NG; Day R
    J Biol Chem; 2016 Nov; 291(47):24676-24687. PubMed ID: 27758865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro.
    Li L; Shen C; Huang YX; Li YN; Liu XF; Liu XM; Liu JH
    Molecules; 2018 Sep; 23(9):. PubMed ID: 30235833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro selection generates RNA aptamer that antagonizes PCSK9-LDLR interaction and recovers cellular LDL uptake.
    Ando T; Yamamoto M; Yokoyama T; Horiuchi D; Kawakami T
    J Biosci Bioeng; 2021 Mar; 131(3):326-332. PubMed ID: 33177004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles.
    Sarkar SK; Foo ACY; Matyas A; Asikhia I; Kosenko T; Goto NK; Vergara-Jaque A; Lagace TA
    J Biol Chem; 2020 Feb; 295(8):2285-2298. PubMed ID: 31949048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove.
    Evison BJ; Palmer JT; Lambert G; Treutlein H; Zeng J; Nativel B; Chemello K; Zhu Q; Wang J; Teng Y; Tang W; Xu Y; Rathi AK; Kumar S; Suchowerska AK; Parmar J; Dixon I; Kelly GE; Bonnar J
    Bioorg Med Chem; 2020 Mar; 28(6):115344. PubMed ID: 32051094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
    Guo S; Xia XD; Gu HM; Zhang DW
    Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational Design, Synthesis, and Biological Evaluation of Diimidazole Analogues Endowed with Dual PCSK9/HMG-CoAR-Inhibiting Activity.
    Lammi C; Fassi EMA; Manenti M; Brambilla M; Conti M; Li J; Roda G; Camera M; Silvani A; Grazioso G
    J Med Chem; 2023 Jun; 66(12):7943-7958. PubMed ID: 37261954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
    Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
    J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor.
    Tombling BJ; Lammi C; Lawrence N; Gilding EK; Grazioso G; Craik DJ; Wang CK
    J Med Chem; 2021 Mar; 64(5):2523-2533. PubMed ID: 33356222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.
    Galvan AM; Chorba JS
    J Lipid Res; 2019 Jan; 60(1):71-84. PubMed ID: 30463987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
    Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
    Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lupin Peptides Modulate the Protein-Protein Interaction of PCSK9 with the Low Density Lipoprotein Receptor in HepG2 Cells.
    Lammi C; Zanoni C; Aiello G; Arnoldi A; Grazioso G
    Sci Rep; 2016 Jul; 6():29931. PubMed ID: 27424515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
    FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regions of conformational flexibility in the proprotein convertase PCSK9 and design of antagonists for LDL cholesterol lowering.
    Kirchhofer D; Burdick DJ; Skelton NJ; Zhang Y; Ultsch M
    Biochem Soc Trans; 2020 Aug; 48(4):1323-1336. PubMed ID: 32794575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.
    Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW
    Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of [5,5'-bibenzo[d][1,3]dioxol]-6-substituted amine derivatives as potent proprotein convertase subtilisin/kexin type 9 inhibitors.
    Zhu D; Qin H; Wang X; Jia Y; Wang X; Zhang L
    Chem Biol Drug Des; 2023 Jul; 102(1):153-167. PubMed ID: 37170061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.